DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our object...

Full description

Bibliographic Details
Main Authors: Carmen Hidalgo-Tenorio, Juan Pasquau, David Vinuesa, Sergio Ferra, Alberto Terrón, Isabel SanJoaquín, Antoni Payeras, Onofre Juan Martínez, Miguel Ángel López-Ruz, Mohamed Omar, Javier de la Torre-Lima, Ana López-Lirola, Jesús Palomares, José Ramón Blanco, Marta Montero, Coral García-Vallecillos
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Viruses
Subjects:
DOLAVI
dolutegravir
lamivudine
real-world data
HIV
Online Access:https://www.mdpi.com/1999-4915/14/3/524

Internet

https://www.mdpi.com/1999-4915/14/3/524

Similar Items